French industrial group Anjac Health & Beauty has acquired food supplements supplier PharmaLinea and now comprises 17 complementary companies with R&D and production capacities in health, beauty, personal care, and food supplements.
The company acquired Health Chain Group (HCG), which is composed of three sister companies in the nutraceutical sector. HCG is led by PharmaLinea, and includes Hermes Consilium (a supplier and distributor of nutritional ingredients) and ErgoPharma (specializing in the manufacturing and analysis of food supplements).
HCG has an integrated model that allows the group to control the entire value chain from ingredients to finished products.
Anjac says the acquisition ties into its broader strategy to strengthen its health and pharma activities, particularly by expanding its nutrition and innovative food ingredients offering.
Working with PharmaLinea, the group anticipates advances for product innovation, scientific research, and services for client brands.
“This marks an exciting new chapter for PharmaLinea. Becoming part of Anjac Health & Beauty represents both a great milestone and a confirmation of how far we’ve come — the culmination of many years of hard work in establishing our company, processes, network, and product pipeline,” says PharmaLinea CEO, Anton Oražem.
“PharmaLinea will gain access to new technologies, innovation possibilities, and partners — all of which will further strengthen our ability to deliver premium, clinically substantiated supplement solutions to our clients.”
Strengthening footprint in high-potential markets
Founded in 2008, Anjac Health & Beauty is a French family-owned industrial group specializing in the formulation, manufacturing, and filling of food supplements as well as cosmetics, medical devices, and pharmaceuticals.
With 17 R&D sites and 24 manufacturing sites across Europe and North America, the group creates, develops, and manufactures raw materials into finished products.
The acquisition also enhances Anjac’s commercial presence in high-potential markets across Central and Eastern Europe, Asia, the Middle East, and North America.
With the move, Anjac Health & Beauty Group has a consolidated workforce of over 3,300 and a 2025 turnover expected of nearly €800 million (US$925.5 million).
Starting out as a single ingredient distribution company, HCG has evolved into a diverse international player in the B2B nutraceutical space, active in over 40 markets globally.
PharmaLinea will retain its distinctive brand identity following the acquisition and will continue to operate as a partner to its international nutraceutical brand clients, while benefiting from Anjac’s infrastructure, cross-sector expertise, and R&D resources.
“PharmaLinea and HCG were founded with a simple yet ambitious goal: to bring more science, integrity, and trust to the nutraceutical industry,” says Blaž Gorjup, chairman and founder of PharmaLinea.
“Joining forces with Anjac will allow HCG to reach even higher while staying true to its values. It’s because of this strong foundation and bright outlook that I chose to remain a minority shareholder and continue to be available to the company as it moves forward.”
Aurélien Chaufour, president of the Anjac Group, adds: “We are delighted to welcome HCG to the Anjac Group. This partnership reflects our strong ambitions in the health and pharma segment, our strategy in clinically backed food and nutraceuticals solutions, and the continued acceleration of our international growth.”
By Benjamin Ferrer
Source: nutritioninsights.com
A phase 2 celiac disease trial of argenx’s FB102 has hit its primary endpoint, delivering a boost to a drug candidate that the biotech acquired in its $2.2 billion takeover of Forte Biosciences. Amsterdam-based argenx agreed to buy Forte in July to acquire FB102, an anti-CD122 antibody that hit the mark in a phase 1b vitiligo trial weeks before the deal.
Bayer announced plans to invest $2.2 billion in a new pharmaceutical manufacturing site in New Albany, Ohio, US. Building on more than seven billion dollars in US pharma R&D and manufacturing spend over the past five years, the project is a central element of Bayer’s long-term growth strategy.
Sterling Pharma Solutions has announced completion of an additional, large-scale GMP manufacturing suite at its dedicated bioconjugation facility in the UK, which will double capacity, as well as increasing the scale of manufacturing to 500L.
